3 Pharma Ingredient Stocks With a Strong Future Roadmap: Acutaas Chemicals, Sudeep Pharma and Anthem Biosciences
- October 7, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Acutaas Rs 3,156.70, P/E 66.70. Sudeep Pharma Rs 1,158.40, P/E 71.22. Anthem Biosciences Rs 890.35, P/E 87.04. Closing prices of 6 Oct 2026.
Quick Answer
Pharma ingredient stocks with the clearest long-term roadmaps today include Acutaas Chemicals in pharmaceutical intermediates and specialty chemicals, including battery electrolyte additives, Sudeep Pharma in pharmaceutical excipients and nutrition ingredients and Anthem Biosciences in contract research, development and manufacturing for pharma and biotech customers. FY26 revenue growth was 34.9% at Acutaas, 31.2% at Sudeep Pharma and 18.1% at Anthem Biosciences. P/E stands at 66.70 for Acutaas (industry 37.19), 71.22 for Sudeep Pharma (industry 35.84) and 87.04 for Anthem Biosciences (industry 37.19). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Pharma ingredient stocks give investors exposure to makers of intermediates, excipients and contract research services that sit behind finished medicines. Results depend on customer contracts, capacity use and operating margin, which is why margin trends matter as much as headline growth.
This list covers three contract research and ingredient stocks: Acutaas Chemicals for pharmaceutical intermediates and specialty chemicals, including battery electrolyte additives, Sudeep Pharma for pharmaceutical excipients and nutrition ingredients and Anthem Biosciences for contract research, development and manufacturing for pharma and biotech customers. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Ingredient Stocks?
Pharma ingredient stocks are shares of companies that supply intermediates, excipients, specialty chemicals and contract research and manufacturing services to drug makers. Results depend on customer contracts, capacity use, regulatory approvals and operating margin, so long customer ties and a wide product range separate the stronger names.
Pharma Ingredient Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three pharma ingredient stocks as of the 6 October 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Acutaas Chemicals | 3,156.70 | 25,836 | 66.70 | 37.19 | 21.54% | 0.02 |
| Sudeep Pharma | 1,158.40 | 13,081 | 71.22 | 35.84 | 19.57% | 0.17 |
| Anthem Biosciences | 890.35 | 50,112 | 87.04 | 37.19 | 19.45% | 0.02 |
Among contract research and ingredient stocks, all three trade at a premium to their industry P/E multiples.
Why Do Pharma Ingredient Stocks Have a Strong Roadmap in India?
Pharma ingredient stocks have a strong roadmap in India because global drug makers diversify supply, India offers cost and skill advantages and companies are adding capacity. Three drivers stand out.
- Supply chain diversification: Global customers want more suppliers outside a single country.
- Contract research growth: Drug makers outsource more development and manufacturing.
- Capacity expansion: New plants support larger contracts and higher volumes.
Acutaas Chemicals: Intermediates and Specialty Chemicals Anchor the Roadmap
Acutaas’ roadmap rests on pharmaceutical intermediates and specialty chemicals, including battery electrolyte additives, with new capacity supporting larger customer contracts.
Revenue grew from Rs 522.90 crore in FY22 to Rs 1,380.95 crore in FY26, a 164.1% rise, and FY26 revenue was 34.9% higher than FY25. FY26 net profit rose 122.1% to Rs 356.37 crore. Over four years, net profit rose from Rs 71.95 crore in FY22 to Rs 356.37 crore. In Q1 FY27, revenue grew 48.5% to Rs 331.47 crore, and net profit rose 70.4% to Rs 74.99 crore. Operating margin was 38.97% in FY26 and 34.84% in Q1 FY27 against 32.26% a year earlier.
Debt to equity is 0.02 and return on equity is 21.54%. FY26 operating cash flow was Rs 292.17 crore against capital expenditure of Rs 327.98 crore. Acutaas paid a dividend of Rs 2.5 per share for FY26, a yield of 0.08%. At a P/E of 66.70 against an industry P/E of 37.19, the stock trades above its industry multiple.
What to watch: FY26 capex of Rs 327.98 Cr was above operating cash flow of Rs 292.17 Cr, and the FY26 operating margin of 38.97% was well above the 24.73% of FY25. The P/E of 66.70 sits above the industry P/E of 37.19, so earnings delivery matters for the valuation.
Sudeep Pharma: Excipients and Nutrition Ingredients Drive the Pipeline
Sudeep Pharma’s roadmap rests on pharmaceutical excipients and nutrition ingredients, with long customer relationships and new capacity supporting volumes.
Revenue grew from Rs 350.40 crore in FY22 to Rs 670.84 crore in FY26, a 91.4% rise, and FY26 revenue was 31.2% higher than FY25. FY26 net profit rose 25.6% to Rs 174.28 crore. Over four years, net profit rose from Rs 50.17 crore in FY22 to Rs 174.28 crore. In Q1 FY27, revenue grew 25.9% to Rs 163.72 crore, and net profit rose 29.8% to Rs 40.59 crore. Operating margin was 39.14% in FY26 and 38.14% in Q1 FY27 against 39.25% a year earlier.
Debt to equity is 0.17 and return on equity is 19.57%. FY26 operating cash flow was Rs 69.55 crore against capital expenditure of Rs 118.15 crore. At a P/E of 71.22 against an industry P/E of 35.84, the stock trades above its industry multiple.
What to watch: FY26 capex of Rs 118.15 Cr was well above operating cash flow of Rs 69.55 Cr, and the company did not pay a dividend for FY26. The P/E of 71.22 sits above the industry P/E of 35.84, so earnings delivery matters for the valuation.
Anthem Biosciences: Contract Research and Manufacturing Build the Next Leg
Anthem Biosciences’ roadmap rests on contract research, development and manufacturing for pharma and biotech customers, with long programmes giving revenue visibility.
Revenue grew from Rs 1,280.24 crore in FY22 to Rs 2,280.12 crore in FY26, a 78.1% rise, and FY26 revenue was 18.1% higher than FY25. FY26 net profit rose 31.1% to Rs 591.79 crore. Over four years, net profit rose from Rs 405.54 crore in FY22 to Rs 591.79 crore. In Q1 FY27, revenue declined 21.3% to Rs 443.11 crore, and net profit fell 11.7% to Rs 119.94 crore. Operating margin was 45.44% in FY26 and 41.95% in Q1 FY27 against 39.67% a year earlier.
Debt to equity is 0.02 and return on equity is 19.45%. FY26 operating cash flow was Rs 844.49 crore against capital expenditure of Rs 211.17 crore. Anthem Biosciences paid a dividend of Rs 2 per share for FY26, a yield of 0.22%. At a P/E of 87.04 against an industry P/E of 37.19, the stock trades above its industry multiple.
What to watch: Quarterly revenue and profit can swing with project timing, as the lower Q1 FY27 figures show. Q1 FY27 net profit was 11.7% lower than a year earlier; the P/E of 87.04 sits above the industry P/E of 37.19, so earnings delivery matters for the valuation.
Best Pharma Ingredient Stocks in India: Acutaas vs Sudeep Pharma vs Anthem Biosciences on Key Financials
Among the best pharma ingredient stocks in India, Anthem Biosciences leads on FY26 operating margin; Acutaas leads on Q1 FY27 revenue growth and five-year revenue growth. The table puts the numbers side by side.
| Metric | Acutaas | Sudeep Pharma | Anthem Biosciences |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 1,380.95 | 670.84 | 2,280.12 |
| FY26 revenue growth | 34.9% | 31.2% | 18.1% |
| Revenue growth FY22 to FY26 | 164.1% | 91.4% | 78.1% |
| FY26 net profit (Rs Cr) | 356.37 | 174.28 | 591.79 |
| FY26 net profit growth | 122.1% | 25.6% | 31.1% |
| FY26 operating profit margin | 38.97% | 39.14% | 45.44% |
| Q1 FY27 revenue growth (YoY) | 48.5% | 25.9% | -21.3% |
| Q1 FY27 net profit growth (YoY) | 70.4% | 29.8% | -11.7% |
| Return on equity | 21.54% | 19.57% | 19.45% |
| P/E ratio | 66.70 | 71.22 | 87.04 |
| Debt to equity | 0.02 | 0.17 | 0.02 |
| Dividend yield | 0.08% | 0.00% | 0.22% |
| FY26 operating cash flow (Rs Cr) | 292.17 | 69.55 | 844.49 |
Ingredient company earnings follow contract timing, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Pharma Intermediate Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen pharma ingredient stocks and shortlist pharma intermediate stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by stock.
- Track operating margin across several quarters, because input costs can move faster than prices.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these pharma ingredient stocks
Risks to Consider Before Investing in Pharma Ingredient Stocks
- Valuation: All three trade well above the industry multiple of about 37.
- Capex: Acutaas and Sudeep Pharma spent more on capex than operating cash flow in FY26.
- Project timing: Anthem Biosciences’ quarterly results swing with project timing.
- Customer concentration: A few large customers can account for a big share of sales.
Download the Univest iOS App or Univest Android App to track Acutaas, Sudeep Pharma and Anthem Biosciences live.
Final Take: Which Stock Has the Strongest Roadmap?
These three pharma intermediate stocks cover pharmaceutical intermediates, excipients and nutrition ingredients, and contract research. Anthem Biosciences leads on FY26 operating margin; Acutaas leads on Q1 FY27 revenue growth and five-year revenue growth.
Across contract research and ingredient stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pharma intermediate stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Pharma Ingredient Stocks
Which are the best pharma ingredient stocks in India with a strong roadmap?
Ans. Acutaas Chemicals, Sudeep Pharma and Anthem Biosciences stand out for their roadmaps in pharma intermediates, excipients and contract research. FY26 revenue growth was 34.9% at Acutaas, 31.2% at Sudeep Pharma and 18.1% at Anthem Biosciences, and return on equity ranges from 19.45% to 21.54%.
Is Acutaas Chemicals a good stock to buy now?
Ans. Acutaas Chemicals has a debt to equity ratio of 0.02, a return on equity of 21.54% and a P/E of 66.70 against an industry P/E of 37.19. Valuation, capex and project timing move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Acutaas, Sudeep Pharma and Anthem Biosciences?
Ans. The P/E ratio is 66.70 for Acutaas (industry 37.19), 71.22 for Sudeep Pharma (industry 35.84) and 87.04 for Anthem Biosciences (industry 37.19). All three trade at or above the industry multiple.
Which of these pharma ingredient stocks has the highest return on equity?
Ans. Acutaas Chemicals has the highest return on equity at 21.54%, followed by Sudeep Pharma at 19.57% and Anthem Biosciences at 19.45%.
What are the risks of investing in pharma ingredient stocks?
Ans. The main risks are high valuations, capex running ahead of cash flow, project timing and customer concentration. Anthem Biosciences trades at 87.04 times earnings against an industry multiple of 37.19.
How did Acutaas, Sudeep Pharma and Anthem Biosciences perform in Q1 FY27?
Ans. Acutaas Chemicals reported revenue of Rs 331.47 crore, up 48.5% year on year, and net profit rose 70.4% to Rs 74.99 crore. Sudeep Pharma reported revenue of Rs 163.72 crore, up 25.9% year on year, and net profit rose 29.8% to Rs 40.59 crore. Anthem Biosciences reported revenue of Rs 443.11 crore, down 21.3% year on year, and net profit fell 11.7% to Rs 119.94 crore.
Do pharma ingredient stocks pay dividends?
Ans. Dividend payouts differ across the three companies. The dividend yield is 0.08% for Acutaas, 0.00% for Sudeep Pharma and 0.22% for Anthem Biosciences, based on dividends declared for FY26.
How can I invest in pharma ingredient stocks in India?
Ans. You can buy pharma ingredient stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
